Table 4.
Clinician Acceptability E – Scale and Feasibility Questionnaire Results (N = 19)
| Adapted Acceptability E – Scalea | Mean (SD, Range) |
|---|---|
| Did use of the Algorithm help you identify appropriate areas of concern related to the assessment and/or management of CIPN symptoms? | 3.05 (1.39, 1–5) |
| Did use of the Algorithm help guide clinical interactions with patients related to the assessment and management of CIPN symptoms? | 2.89 (1.29, 1–5) |
| Was the Algorithm helpful in promoting communication between you and your patients related to the assessment and management of CIPN symptoms? | 3.21 (1.4, 1–5) |
| Was the Algorithm helpful in identifying areas of need or symptoms related to CIPN? | 3.11 (1.15, 1–5) |
| Was use of the Algorithm helpful in promoting your knowledge related to the assessment and/or management of CIPN symptoms? | 2.95 (1.13, 1–5) |
| How understandable was the content presented within the Algorithm? | 3.95 (1.13, 1–5) |
| How easy was it to use the Algorithm during your clinical interactions with patients? (n = 18) | 3.39 (1.14, 1–5) |
| Overall, how would you rate your satisfaction with the Algorithm? | 3.11 (0.94, 1–5) |
| Feasibility Questionnaireb | |
| When you received the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Symptom Assessment Summary (sheet displaying patients’ CIPN severity scores) and the CIPN Assessment and Management Algorithm, how often did you use the CIPN Symptom Assessment Summary or Assessment and Management Algorithm to aid you in the assessment and management of CIPN during those particular clinic visits? | 2.58 (0.9, 1–4) |
| We sent you several other education materials (i.e., neuropathy safety information, vibration sensibility and deep-tendon reflexes training video, CIPN clinical practice guideline) via email before you began using the CIPN Assessment and Management Algorithm. You most likely received this email around February or March 2019. From the time that you received the email containing the materials, did you review or use the materials we provided to you to aid in the assessment and/or management of CIPN symptoms? | 1.89 (0.81, 1–3) |
Table 4 describes clinicians’ mean scores on the Adapted Acceptability E – Scale and Feasibility Questionnaire in regard to the CIPN algorithm at the end of the study
aThe Adapted Acceptability E – Scale items were scored from 1 to 5, with higher scores indicating greater acceptability or satisfaction
bThe Feasibility Questionnaire items were scored from 1 to 5 (i.e., 1 = Never, 2 = Seldom, 3 = Sometimes, 4 = Frequently, 5 = Always)